Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 313: HIV Vaccine Regimens in Healthy Adults
NCT06332339Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2024
- Primary completion
- Nov 2026
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 16055 NFL delta Gly4 trimer, trimer 4571 and Ad4-Env145NFL in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local reactogenicity signs and symptoms, Systemic reactogenicity signs and symptoms and 4 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
16055 NFL delta Gly4 trimertrimer 4571Ad4-Env145NFL
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06332339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332339.